MIRACOR ANNOUNCES FDA IDE APPROVAL
FOR PiCSO PIVOTAL STUDY
NEWS
Press Releases, Meetings & Company News
NEWS
Press Releases & Meetings
NEWS
Press Releases & Meetings
PRESSURE-CONTROLLED INTERMITTENT CORONARY OCCLUSION IMPROVES THE VASODILATORY MICROVASCULAR CAPACITY AND REDUCES MYOCARDIAL INJURY IN PATIENTS WITH STEMI.
Scarsini R, Terentes-Printzios D, Shanmuganathan M, Kotronias RA, Borlotti A, Marin F, Langrish J, Lucking A, Ribichini F; OxAMI Study, Kharbanda R, Ferreira VM, Channon KM, De Maria GL, Banning AP.
-
Miracor Announces FDA IDE Approval for PiCSO Pivotal Study.
Miracor Announces FDA IDE Approval for PiCSO Pivotal Study.
-
Miracor Medical starts 2nd randomized study, targeting expanded indications.
Miracor Medical starts 2nd randomized study, targeting expanded indications.
-
Miracor Medical raises 24M€
Miracor Medical raises 24M€
-
Miracor Medical awarded CE Mark for PiCSO Impulse Catheter and Console
Miracor Medical awarded CE Mark for PiCSO Impulse Catheter and Console
-
Miracor Medical announces PiCSO presentations during PCR e-Course
Miracor Medical announces PiCSO presentations during PCR e-Course
-
Miracor Medical granted FDA Breakthrough Device Designation for the PiCSO therapy
Miracor Medical granted FDA Breakthrough Device Designation for the PiCSO therapy
-
Miracor Medical starts PiCSO-AMI-I randomized study in EU
Miracor Medical starts PiCSO-AMI-I randomized study in EU
-
Miracor Medical closes final tranche of Series-D bringing the round to 30€M
Miracor Medical closes final tranche of Series-D bringing the round to 30€M
-
Interview of Olivier Delporte, CEO Miracor Medical SA – interview in French
Interview of Olivier Delporte, CEO Miracor Medical SA – interview in French
-
EuroPCR 2018 Presentations – Paris, France, May 25-22
EuroPCR 2018 Presentations – Paris, France, May 25-22
